Brivanib Metastatic Renal Cell Carcinoma
Stopped In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.
Conditions
Interventions
- DRUG: Brivanib alaninate
- GENETIC: Polymerase chain reaction
- OTHER: Iodine I 124 chimeric monoclonal antibody G250
- PROCEDURE: Positron emission tomography/computed tomography
- GENETIC: Protein expression analysis
- OTHER: Immunohistochemistry
Sponsor
Abramson Cancer Center at Penn Medicine